Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro

Background Thyroid cancer is the most common endocrine malignancy.

Current therapies are successful, however some patients progress to therapeutically refractive disease.

The immunotherapeutic potential of the CXCL8-chemokine/CXCR2-chemokine-receptor system is currently being explored in numerous human cancers.

This study aimed to evaluate if the targeting of CXCR2 by its selective antagonist, AZD5069, could modulate CXCL8-mediated pro-tumorigenic effects in thyroid-cancer (TC) cells in vitro.

Methods Normal human primary thyroid cells (NHT) and TC cell lines TPC-1 (RET/PTC), BCPAP, 8505C and 8305C (BRAFV600e) were treated with AZD5069 (100 pM-10 µM) over a time-course.

Viability and proliferation were assessed by WST-1 and crystal violet assays.

CXCL8 and CXCR2 mRNA were evaluated by RT-PCR.

CXCL8-protein concentrations were measured in cell culture supernatants by ELISA.

CXCR2 on cell surface was evaluated by flow-cytometry.

Cell-migration was assessed by trans-well-migration chamber-system.

Results AZD5069 exerted negligible effects on cell proliferation or viability.

AZD5069 significantly reduced CXCR2, (but not CXCL8) mRNAs in all cell types.

CXCR2 was reduced on the membrane of some TC cell lines.

A significant reduction of the CXCL8 secretion was found in TPC-1 cells (basal-secretion) and NHT (TNFα-induced secretion).

AZD5069 significantly reduced basal and CXCL8-induced migration in NHT and different TC cells.

Conclusions Our findings confirm the involvement of the CXCL8/CXCR2-axis in promoting pro-tumorigenic effects in TC cells, further demonstrating its immunotherapeutic significance in human cancer.